|
|
Kogle All� 6, H�rsholm
Danmark, DK 2970 Denmark
phone:45 45 17 98 00
fax:+45 45179887
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.santaris.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| New drugs against cancer |
|
| Management |
| Keith McCullagh, PhD, BVSc, MRCVS, President & CEO.; Henrik ?rum, M.Sc., Ph.D, Vice President & CSO; Troels Koch, M.Sc, Ph.D, Vice President of Drug Discovery & Manufacture; Lene Worsaae Dalby, M.D., Vice President of Clinical Development, Henrik Stage, M.Sc., Vice President, Finance and Administration, & CFO |
| |
|
|
| |
|
| Keywords |
| drugs, cancer, gene, molecule, sensor, apoptotic, machinery, lna, inhibitor, protein, intracellular, prognosis, dna, lna, pna, nucleic, acid, peptide |
|
|
|
| Description |
|
Santaris Pharma concentrates on the research and development of new drugs against cancer. "Santaris Pharma is a Danish based clinical-stage biopharmaceutical company pioneering the use of potent single-stranded antisense
oligonucleotides called messengerRNA Antagonists and microRNA antagonists. Santaris Pharma's drugs are made from an analogue
of RNA known as Locked Nucleic Acid (LNA) to which the Company has world wide exclusive pharmaceutical rights. Santaris
Pharma's most advanced mRNA antagonist has shown initial efficacy and safety in human clinical trials and its most advanced
miRNA antagonist has demonstrated microRNA silencing in non-human primates. This drug candidate is currently being tested in a
First-in-Man clinical trial. Santaris Pharma's therapeutic focus is cancer, metabolic diseases and viral diseases." |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members